Treatment Information

Back

Liver Cancer treatment details. Chemotherapy.

Karmanos Cancer Institute, Detroit, MI, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Detroit, MI
Treatments:ChemotherapyHospital:Karmanos Cancer Institute
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This Phase II study involved 38 patients with advanced hepatocellular cancer, fifteen of whom had metastases (including lung, liver, bone, and lymph nodes). Twenty-six patients were men, and sixteen were women. The median age was 69 years. Twenty-two patients had prior chronic liver disease, eighteen had prior chemotherapy. Tumors were unresectable for 33 patients.

Treatment: The treatment consisted of one chemotherapeutic agent: erlotinib.

Toxicity: Grade 1-4 toxicities included skin rash, diarrhea, and fatigue.

Results: The median overall survival was 13 months. Three patients had a partial response to treatment, and stable disease was briefly achieved for 17 patients. The authors were encouraged by these results and suggested further study for using erlotinib for liver cancer patients.

Correspondence: Philip Agop Philip, MD, Ph.D.



Back